Project/Area Number |
26462357
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Anesthesiology
|
Research Institution | Mie University |
Principal Investigator |
Yokochi Ayumu 三重大学, 医学部附属病院, 講師 (60359768)
|
Co-Investigator(Kenkyū-buntansha) |
丸山 一男 三重大学, 医学系研究科, 教授 (20181828)
澤田 博文 三重大学, 医学系研究科, 講師 (30362354)
張 尓泉 三重大学, 医学系研究科, 助教 (30456727)
|
Research Collaborator |
MARUYAMA Junko
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 肺高血圧 / スーパーオキシド / キサンチンオキシダーゼ / フェブキソスタット / Febuxostat / 一酸化窒素 / モノクロタリン / 低酸素 / uncoupled NOS / 肺高血圧症 |
Outline of Final Research Achievements |
Febuxostat, being a novel xanthine oxidase inhibitor, is apparently having a beneficial role in improving the endothelial dysfunction. The purpose of the present study was to investigate whether febuxostat (FBS) prevents the development of pulmonary hypertension (PH) in both monocrotaline (MCT)-injected rats and in rats exposed to chronic hypobaric hypoxia (CH)(380 mm Hg, 10% oxygen). The mean pulmonary artery pressure (mPAP), right ventricular hypertrophy (RVH), percentages of muscularized peripheral arteries (%muscularization), and medial wall thickness of small muscular arteries (%MWT) were measured. MCT increased mPAP, RVH, %muscularization, and %MWT.CH increased mPAP, RVH, %muscularization, and %MWT.FBS treatment did not significantly reduced mPAP, RVH, %muscularization, and %MWT in both MCT-injected rats and in rats exposed to CH. FBS does not appear to prevent the development of pulmonary hypertension (PH) in both MCT-injected rats and in rats exposed to CH.
|